Roches fenebrutinib is the first investigational medicine in over a decade that reduces disability progression in primary progressive multiple sclerosis (PPMS)
Late-breaking Phase III FENtrepid results presented at ACTRIMS show investigational fenebrutinib met…
JASCAYD (nerandomilast) receives first regulatory approval for progressive pulmonary fibrosis in China
The approval marks the first new treatment option for people living with…
